deltatrials
Completed PHASE3 NCT00095238

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Sponsor: Bristol-Myers Squibb

Conditions Congestive Heart Failure
Interventions Irbesartan Placebo
Updated 7 times since 2017 Last updated: Mar 18, 2015 Started: Jun 30, 2002 Primary completion: Jul 31, 2008 Completion: Jul 31, 2008

This PHASE3 trial investigates Congestive Heart Failure and is currently completed. Bristol-Myers Squibb leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Sanofi
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain, Aalst, Belgium, Abbeville, France, Aguascalientes, Mexico, Ajax, Canada, Albany, United States, Albuquerque, United States, Alkmaar, Netherlands, Almere Stad, Netherlands, Amersfoort, Netherlands and 218 more location s